LNSR
LENSAR, Inc.NASDAQHealthcare$6.06+1.51%ClosedMarket Cap: $72.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.73
P/S
1.20
EV/EBITDA
-2.99
DCF Value
$-45.58
FCF Yield
-21.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
46.4%
Operating Margin
-40.5%
Net Margin
-58.7%
ROE
197.2%
ROA
-48.0%
ROIC
-74.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $16.0M | 44.7% | $-4.0M | $-1.5M | $-0.12 | — |
| FY 2025 | $58.4M | 46.4% | $-23.7M | $-34.3M | $-2.87 | — |
| Q3 2025 | $14.3M | 40.6% | $-7.6M | $-3.7M | $-0.31 | — |
| Q2 2025 | $13.9M | 50.4% | $-6.3M | $-1.8M | $-0.15 | — |
| Q1 2025 | $14.2M | 50.3% | $-5.8M | $-27.3M | $-2.32 | — |
| Q4 2024 | $16.7M | 42.5% | $-1.3M | $-18.7M | $-1.61 | — |
| FY 2024 | $53.5M | 48.3% | $-10.7M | $-31.4M | $-2.73 | — |
| Q3 2024 | $13.5M | 46.3% | $-1.0M | $-1.5M | $-0.13 | — |
| Q2 2024 | $12.6M | 52.1% | $-1.6M | $-9.0M | $-0.79 | — |
| Q1 2024 | $10.6M | 50.9% | $-2.9M | $-2.2M | $-0.19 | — |
| Q4 2023 | $12.1M | 40.3% | $-3.0M | $-3.9M | $-0.35 | — |
| FY 2023 | $42.2M | 50.1% | $-12.2M | $-14.4M | $-1.31 | — |